BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2025.
World J Transplant. Dec 18, 2025; 15(4): 106938
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.106938
Table 2 Sociodemographics, clinical characteristics, outcomes, and treatment, n (%)
Characteristics
Full cohort (n = 79)
Recurrent AILD (n = 21)
Non-recurrent AILD (n = 58)
Odds ratio (95%CI)
P value
Age at diagnosis (years) (mean ± SD)41.03 ± 11.9437.29 ± 12.4842.38 ± 11.550.96 (0.92-1.00)0.098
Time from diagnosis to LT (years) (mean ± SD)6.24 ± 4.156.48 ± 4.136.16 ± 4.191.01 (0.90-1.14)0.760
Age at LT (years) (mean ± SD)47.14 ± 11.7543.76 ± 11.9948.36 ± 11.530.96 (0.92-1.00)0.128
Sex
Male24 (30.4)6 (28.6)18 (31.0)0.88 (0.29-2.66)0.833
Female55 (69.6)15 (71.4)40 (69.0)1.0 (ref)
Socioeconomic status1
111 (13.9)4 (19.0)7 (12.1)Ref-
232 (40.5)10 (47.6)22 (37.9)0.79 (0.18-3.35)0.755
320 (25.3)5 (23.8)15 (25.9)0.58 (0.11-2.86)0.507
46 (7.6)0 (0.0)6 (10.3)--
52 (2.5)1 (4.8)1 (1.7)1.75 (0.08-36.28)0.718
61 (1.3)1 (4.8)0 (0.0)--
77 (8.9)0 (0.0)7 (12.1)--
Family history of autoimmune disease2,312 (20.3)3 (20.0)9 (20.5)0.97 (0.22-4.19)0.970
Concomitant autoimmune disease423 (29.1)7 (33.3)16 (27.6)1.31 (0.44-3.84)0.620
Comorbidities
Type 2 diabetes mellitus9 (11.4)2 (9.5)7 (12.1)0.76 (0.14-4.02)0.754
Chronic hypertension6 (7.6)0 (0.0)6 (10.3)--
Hypothyroidism13 (16.5)3 (14.3)10 (17.2)0.80 (0.19-3.24)0.755
Chronic kidney disease4 (5.1)1 (4.8)3 (5.2)0.91 (0.09-9.33)0.941
AILD etiology
AIH30 (38.0)8 (38.1)22 (37.9)Ref-
PBC19 (24.1)4 (19.0)15 (25.9)0.73 (0.18-2.87)0.657
AIH/PBC overlap17 (21.5)6 (28.6)11 (19.0)1.50 (0.41-5.40)0.535
PSC10 (12.7)3 (14.3)7 (12.1)1.17 (0.24-5.69)0.838
PSC/AIH overlap2 (2.5)0 (0.0)2 (3.4)--
PSC/PBC overlap1 (1.3)0 (0.0)1 (1.7)--
Child-Pugh score (mean ± SD)10.86 ± 1.8311.61 ± 1.1610.58 ± 1.961.43 (1.03-2.00)0.032
MELD score (mean ± SD)19.86 ± 7.0122.76 ± 5.4718.81 ± 7.241.08 (1.01-1.16)0.032
MELD-Na score (mean ± SD)22.49 ± 6.8124.71 ± 5.4121.69 ± 7.121.06 (0.99-1.15)0.085
Chronic liver disease complications5
Esophageal varices666 (91.7)16 (88.9)50 (92.6)0.64 (0.10-3.82)0.625
Portal thrombosis711 (14.7)3 (15.8)8 (14.3)1.12 (0.26-4.76)0.873
Hepatic encephalopathy57 (72.2)14 (66.7)43 (74.1)0.69 (0.23-2.05)0.514
Ascites70 (88.6)20 (95.2)50 (86.2)3.20 (0.37-27.26)0.287
Spontaneous bacterial peritonitis823 (30.3)8 (40.0)15 (26.8)1.82 (0.62-5.32)0.273
Hepatorenal syndrome96 (7.7)1 (4.8)5 (8.8)0.52 (0.05-4.73)0.562
Infection history 6 months after LT46 (58.2)12 (57.1)34 (58.6)0.94 (0.34-2.58)0.906
History of acute transplant rejection1012 (15.2)4 (19.0)8 (13.8)1.47 (0.39-5.50)0.567
Treatment following LT
Basiliximab1157 (93.4)16 (94.1)41 (93.2)1.17 (0.11-12.10)0.895
Methylprednisolone1271 (100)18 (85.71)53 (91.37)--
Tacrolimus1372 (98.6)21 (100)51 (98.1)--
Mycophenolate1364 (87.7)18 (85.7)46 (88.5)0.78 (0.17-3.46)0.747
Cyclosporine138 (11.0)0 (0.0)8 (15.4)--
Prednisone1373 (100)21 (100)52 (100)--


Write to the Help Desk